Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 37

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 37
---
 genetically modified cells targeted to treat cancer and HIV, and we rely on third parties under contract in
the development of product candidates in our pipeline. There is no guarantee that we will be able to manage and fund the development of
a pipeline with multiple target conditions, nor that third parties will meet their obligations to us in connection with our research and
development. We and certain third parties, on which we rely, have no relevant operating history upon which an evaluation of our performance
and prospects can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited to,
risks of unforeseen capital requirements, failure of treatments either in non-clinical testing or in clinical trials, failure to establish
business relationships, failure of our third parties to meet their obligations to us and competitive disadvantages against larger and
more established companies. If we fail to become profitable, we may suspend or cease operations.

Renovaro Cube is an artificial intelligence (“AI”)-driven healthcare technology company operating in a rapidly evolving field and has a limited operating history, which makes it difficult to evaluate Renovaro Cube’s current business and predict Renovaro Cube’s future performance.

Renovaro
Cube is an AI-driven healthcare technology company operating in a rapidly evolving field and, having commenced operations in 2013,
has a limited operating history. Renovaro Cube shifted its business from the financial technology (or FinTech) industry to cancer diagnostics
in 2018. We currently do not have a commercial product for sale. We have never generated any revenue relating to our cancer diagnostics
AI platform. Renovaro Cube’s short operating history makes any assessment of its current business or future success and viability
subject to significant uncertainty. We expect to encounter risks and difficulties, including those frequently experienced by early-stage companies
in rapidly evolving fields. If we do not address these risks and difficulties successfully, our business will suffer.

Renovaro Cube has a history of net losses and anticipates that it may continue to incur net losses for the foreseeable future.

Grace
Systems (Renovaro Cube’s predecessor) has primarily incurred net losses since its inception in 2013 and has never generated any
revenue relating to its cancer diagnostics AI platform. Renovaro Cube anticipates that it may continue to incur primarily net losses in
the foreseeable future. Renovaro Cube has invested significant financial resources in research and development activities, including to
develop its technology and investigational products and plan for commercial launch of its AI